You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PARP-inhibitor

Showing 1 - 25 of 7,705
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor Trial (CVL218)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Oct 9, 2023

Metastatic Breast Cancer Trial in Herlev, Vejle (PARP inhibitor 2X-121)

Active, not recruiting
  • Metastatic Breast Cancer
  • PARP inhibitor 2X-121
  • Herlev, Denmark
  • +1 more
Feb 1, 2023

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting
  • PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 4, 2022

Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Ovarian Cancer, Drug Related Tumor/Cancer Trial (secondary cytoreductive surgery, chemo)

Not yet recruiting
  • Ovarian Cancer
  • Drug Related Neoplasm/Cancer
  • (no location specified)
Jan 28, 2023

Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin Trial in Belgium, Netherlands, United Kingdom

Active, not recruiting
  • Triple Negative Metastatic Breast Cancer
  • +3 more
  • KU-0059436 (AZD2281)(PARP inhibitor)
  • +3 more
  • Brussels, Belgium
  • +3 more
Dec 19, 2022

Brain Metastases Trial in Houston (Niraparib, Dostarlimab)

Not yet recruiting
  • Brain Metastases
  • Houston, Texas
    M D Anderson Cancer Center
Jan 17, 2023

Ovarian Cancer Trial (JPI-547)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 24, 2022

Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

Not yet recruiting
  • Breast Cancer
  • +7 more
  • (no location specified)
Sep 26, 2023

Advanced Solid Tumor, NSCLCs Trial in Houston (Adagrasib, Olaparib)

Not yet recruiting
  • Advanced Solid Tumor
  • Non-small Cell Lung Cancers
  • Houston, Texas
    M D Anderson Cancer Center
Nov 15, 2023

Ovarian Tumors, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer Trial in Beijing (AK112 low dose, AK112 medium dose, AK112

Terminated
  • Ovarian Neoplasms
  • +3 more
  • AK112 low dose
  • +2 more
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences and Peking Union Medical Col
Oct 8, 2022

Head and Neck Squamous Cell Carcinoma Trial in Brescia (Niraparib)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Brescia, Italy
    Asst Degli Spedali Civili Di Brescia
Aug 3, 2022

Metastatic Cancer, Unspecified Adult Solid Tumor Trial in Los Angeles (PARP inhibitor BMN-673, temozolomide, irinotecan HCl)

Completed
  • Metastatic Cancer
  • Unspecified Adult Solid Tumor
  • PARP inhibitor BMN-673
  • +4 more
  • Los Angeles, California
    Jonsson Comprehensive Cancer Center
Sep 22, 2022

Endometrial Cancer Trial in Hong Kong (Olaparib)

Not yet recruiting
  • Endometrial Cancer
  • Hong Kong, Hong Kong
    The University of Hong Kong
Apr 2, 2022

Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))

Active, not recruiting
  • Ovarian Neoplasms
  • +2 more
  • KU-0059436 (AZD2281)(PARP inhibitor)
  • Brussels, Belgium
  • +4 more
Dec 19, 2022

Acute Myeloid Leukemia Trial in Stanford (Talazoparib, Topotecan, Gemcitabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Stanford, California
    Stanford University
Jun 10, 2022

Ovarian Cancer, Fatigue, Coping Behavior Trial in Boston, Philadelphia (Enhanced Usual Care (EOC), REVITALIZE ACT Intervention)

Active, not recruiting
  • Ovarian Cancer
  • +3 more
  • Enhanced Usual Care (EOC)
  • REVITALIZE ACT Intervention
  • Boston, Massachusetts
  • +1 more
Jun 13, 2022

Lung Cancer Trial in Tianjin (PD-1 inhibitor, PARP inhibitor)

Recruiting
  • Lung Cancer
  • PD-1 inhibitor
  • PARP inhibitor
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
May 23, 2022

Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

Recruiting
  • Platinum-Refractory Fallopian Tube Carcinoma
  • +11 more
  • Copanlisib Hydrochloride
  • +4 more
  • Aurora, Colorado
  • +2 more
Dec 8, 2022

Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers Trial (Niraparib)

Not yet recruiting
  • Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
  • (no location specified)
Feb 21, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial (procedure, biological,

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +5 more
  • (no location specified)
Apr 8, 2023

Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
Aug 8, 2022

Prostate Cancer, Castration-resistant Prostate Cancer Trial in Washington, Baltimore (Olaparib, Vitamin C)

Not yet recruiting
  • Prostate Cancer
  • Castration-resistant Prostate Cancer
  • Washington, District of Columbia
  • +1 more
Aug 12, 2022

Breast Tumors Trial in Worldwide (KU-0059436 (AZD2281) (PARP inhibitor))

Completed
Has Results
  • Breast Neoplasms
  • KU-0059436 (AZD2281) (PARP inhibitor)
  • West Hollywood, California
  • +16 more
Jan 24, 2023

Ovarian Cancer, Breast Cancer, Solid Tumor Trial in Houston, Brisbane (CYH33)

Recruiting
  • Ovarian Cancer
  • +4 more
  • New Haven, Connecticut
  • +6 more
Oct 10, 2022